IN THE SPOTLIGHT

Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment

Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment

Beyond the membrane: rethinking EGFR signaling in physiology and cancer

Beyond the membrane: rethinking EGFR signaling in physiology and cancer

Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Targeting ABCA3 impedes tumor progression and EGFR-TKI resistance in EGFR-mutant LUAD

Targeting ABCA3 impedes tumor progression and EGFR-TKI resistance in EGFR-mutant LUAD

A c-Cbl/Cbl-b antagonist inhibits EGFR ubiquitylation and sustains EGFR phosphorylation to enhance corneal re-epithelialization

A c-Cbl/Cbl-b antagonist inhibits EGFR ubiquitylation and sustains EGFR phosphorylation to enhance corneal re-epithelialization

Editorial expression of concern: Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

Editorial expression of concern: Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway